Q1 2025 Lisata Therapeutics Inc Earnings Call Transcript

May 8, 2025 / 08:30 PM GMT

Release Date Price: $2.37 (+3.26%)

Transcript 10-Q8-K

Key Points

Positve

Lisata Therapeutics Inc (LSTA) reported a decrease in operating expenses by 11.4% year-over-year, indicating effective cost management.
The company has made significant progress in advancing its clinical development portfolio, particularly with the novel product candidate certepatide targeting solid tumors.
Preliminary results from the Ascend trial and Ilia trial data presented at the 2025 ASCO GI symposium showed promising potential for certepatide.
Lisata Therapeutics Inc (LSTA) has secured multiple special designations from both the FDA and EMA for certepatide, enhancing its regulatory standing.
The company has established several collaborations to explore new strategic development opportunities for certepatide, including partnerships with Belo Therapeutics and Catalan.

Negative

Despite progress, Lisata Therapeutics Inc (LSTA) faces persistent market headwinds for small-cap healthcare companies.
The company's net losses were $4.7 million for the first quarter of 2025, although this is an improvement from the previous year.
Enrollment completion for certain trials, such as the glioblastoma multiforme study, is not expected until 2026, indicating long timelines for some projects.
The company has limited control over study timelines for investigator-initiated trials, which may affect expectations and outcomes.
Lisata Therapeutics Inc (LSTA) is operating in a challenging financial environment, which necessitates careful management of resources and may impact the pace of development.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

LSTA.OQ - Lisata Therapeutics Inc
Q1 2025 Lisata Therapeutics Inc Earnings Call
May 08, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to the Assada Therapeutics first quarter 2025 financial results and business update conference call. Currently all participants are in listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press 11 on your telephone. You will then hear an automated message advising your hand is raised.

As a reminder, this call is being recorded today, Thursday, May 8, 2025. I will now turn the call over to John Mendito, Vice President of Investor relations and corporate communications at Assada. Please go ahead, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.